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Abstract 
A series of novel cyclopent[b]indole analogues that hold isoxazolo-, pyrido- templates 
were designed and synthesised in good yields. The in vitro cytotoxicity was concerned for all the 
newly synthesized compounds by MTT assay against HeLa (cervix adeno carcinoma) and MCF-
7 (breast cancer). These synthesised compounds were further compared with the standard drug 
ellipticine, 5-Fluorouracil, Cisplatin and Methotrexate. The synthesised hetero annulated 
cyclopent[b]indole compounds were found to show better cytotoxic activity against HeLa and 
MCF-7 with primary structure activity relationship (SAR) studies. In order to identify with the 
nature of interactions of these molecules we carried out molecular docking studies using the 
protein kinase CK2 inhibitors. The docking results afforded some valuable information for the 
future design of more potent inhibitors. 
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1. Introduction 
Indole derivatives condensed with different heterocycles are physiologically active 
compounds found in abundance in materials such as pharmaceuticals, alkaloids and potential 
therapeutic agents.1 The indole nucleus presents in a large number of naturally occurring as well 
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as biologically active molecules, which makes indole molecules of considerable contemporary 
interest and importance.2 Cyclopent[b]indole occurs in a large number of alkaloids, including the 
structurally complex tremorgenic mycotoxines3 such as paxilline, paspaline, lolitrems, 
janthitrems and yuehchukene (Figure.1).4 Among the alkaloids, those containing 
cyclopent[b]indole5 units were found to exhibit potential antimicrobial, anti-inflammatory, 
antioxidant, anti-implantation and tremorgenic activities.6 Though many numbers of reports were 
available on the synthesis of several functionalized carbazoles,7 the corresponding work on the 
synthesis and utilization of cyclopent[b]indole seems to be less recognized. Therefore, it is 
essential to pay more attention for the development of new method towards the synthesis of 1-
oxo-1,2,3,8-tetrahydrocyclopent[b]indoles and employ them as synthon for the construction of 
many annulated heterocyclic systems possessing cyclopent[b]indole moiety.8 
A heterocyclic isoxazoles and pyridines are well known to be an important class of 
compounds with a wide range of biological activities like antimicrobial, anticancer etc.9 In 
earlier work from our lab, we have reported the synthesis of hetero annulated carbazoles.10 In 
view of the growing importance of cyclopent[b]indole alkaloids, it is contemplated to synthesise 
1-oxo-1,2,3,8-tetrahydrocyclopent[b]indoles which can be used as an important precursor for the 
construction of a wide range of heterocyclo-fused compounds possessing significant 
pharmacological activities. The innovation directs for pharmaceutical explorations and further 
needs recognition of novel molecules that are able to interrelate with and modify a biological 
target. Protein kinases CK2 is a ubiquitous and represents a major therapeutic target of its 
contribution in numerous oncogenic signalling pathways and CK2 kinase inhibitors have 
established powerful clinical activity in pathologies in which the target kinase is dysregulated.11 
Herein we report to achieve hetero annulated cyclopent[b]indoles, the precursor, 5-methyl-1-
oxo-1,2,3,8-tetrahydrocyclopent[b] indole (1) was obtained by Fischer indole cyclization of the 
respective hydrazone, which inturn obtained by the Japp-Klingeman method of diazotized p-
methylaniline derivative with 2-hydroxymethylenecyclo pentanone.12 The synthesis of 4,9-
dihydro-3-(thiophen-2'-yl)-6-methylisooxazolo[2,3-a]cyclopent[b]indole (4) and 5,10-dihydro-2-
ethoxy-4-(2'-aryl)-7-methylpyrido[2,3-a]cyclopent[b]indole-3-carbonitrile (5) starting from the 
easily accessible 5-methyl-1-oxo-1,2,3,8-tetrahydrocyclopent[b]indole (1) through the 
intermediate, 5-methyl-2-(2'-arylidine)-1-oxo-1,2,3,8-tetrahydrocyclopent[b]indole (3). We 
envisioned the earlier validation and furtherance of an improvement program intending to find a 
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new structure directs with potential cytotoxic activities, a new series of benzylidene-, isoxazolo-, 
and pyrido- cyclopent[b]indoles have been synthesized and screened for their in vitro cytoxicity 
against HeLa (cervix adeno carcinoma) and MCF-7 (breast cancer). The goal of looking these 
hybrids is an attempt to attain an active antitumor agent with potentiated activity and selectivity 
toward cancerous cells. Moreover drug-likeness and molecular docking methodology were used 
to identify the structural features required for the antitumor properties of this new series. 
 
2. Results and discussion 
2.1. Chemistry 
An equimolar mixture of 5-methyl-1-oxo-1,2,3,8-tetrahydrocyclopent[b]indole (2) and 
thiophene-2-carbaldehyde (3a) was treated with 25 mL of a 5% alcoholic potassium hydroxide 
solution and stirred at room temperature for 24 hrs to yield 5-methyl-2-(thiophen-2'-ylidine)-1-
oxo-1,2,3,8-tetrahydrocyclopent[b]indole (4a) (Scheme 1). Its FT-IR (KBr, cm-1) spectrum  
showed two characteristic peaks at 3187 cm-1 and 1662 cm-1 corresponding to NH and C=O 
stretching vibrations. Its 1H-NMR (400 MHz) spectrum in DMSO-d6 exhibited the following 
peaks. A three proton singlet appeared at δ 2.404 was due to CH3 protons. A two proton singlet 
appeared at δ 3.862 was due to C3-2H aliphatic protons. A two proton multiplet between δ 7.186-
7.241 was due to C4- and C6- protons. One proton doublet at δ 7.340 was due to C7-H proton 
with J = 8.40 Hz. The three proton multiplet between δ 7.576-7.602 was due to C3'-, C4'- and C5'- 
protons. A one proton triplet appeared at δ 7.866 was due to arylidine olefinic proton with J = 
4.00 Hz. One proton singlet appeared at δ 11.747 was due to N-H proton. Its 13C NMR (100 
MHz, DMSO-d6) spectrum indicates the presence of 17 carbons. All details attest the structure of 
the compound as 5-methyl-2-(thiophen-2'-ylidine)-1-oxo-1,2,3,8-tetrahydrocyclopent[b]indole 
(4a). The generality (Scheme 1, Table 1) of the reaction was tested, other arylaldehyde 
derivatives (3) and 5-methyl-1-oxo-1,2,3,8-tetrahydrocyclopent[b]indole (2) with which gave the 
corresponding 5-methyl-2-(2'-arylidine)-1-oxo-1,2,3,8-tetrahydrocyclopent[b] indole derivatives 
(4) and their structures were verified by FT-IR, NMR spectroscopic methods and elemental 
analysis. Furthermore the structure of compound 4d was unambiguously confirmed by single 
crystal x-ray diffraction studies (Fig. 2). 
The reaction of 5-methyl-2-(thiophen-2'-ylidine)-1-oxo-1,2,3,8-tetrahydrocyclopent[b] 
indole (4a) with hydroxylamine hydrochloride in pyridine yielded 4,9-dihydro-3-(thiophen-2'-
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yl)-6-methylisooxazolo[2,3-a]cyclopent[b]indole (5a) (Scheme 1). Its FT-IR (KBr, cm-1) 
spectrum showed two characteristic peaks at 3342 cm-1 and 1662 cm-1 corresponding to NH and 
C=N stretching vibrations. Its 1H-NMR (400 MHz, DMSO-d6) spectrum in DMSO-d6 exhibited 
the following peaks. A three proton singlet appeared at δ 2.390 was due to CH3 protons. A two 
proton appeared as a singlet at δ 3.790 was due to C4-2H protons. A one proton doublet appeared 
at δ 7.041 was due to C8- proton with J = 8.40 Hz. One proton multiplet between δ 7.160-7.180 
was due to C7- proton. The three proton multiplet between δ 7.358-7.411 was due to C3'-, C4'- 
and C5'- protons. One proton singlet appeared at δ 7.472 was due to C5- proton. One proton 
singlet appeared at δ 11.265 was due to N-H proton. Its 13C NMR (100 MHz, DMSO-d6) 
spectrum indicates the presence of 17 carbons. The elemental analysis of the compound 5a is in 
good agreement with the proposed molecular formula C17H12N2OS which also gave considerable 
support to the structure of 5a. The generality (Scheme 1, Table 1) of the reaction was 
investigated on other 5-methyl-2-(2'-arylidine)-1-oxo-1,2,3,8-tetrahydrocyclopent[b]indole 
derivatives (4b-h) with hydroxylamine hydrochloride in pyridine, which gave the corresponding 
4,9-dihydro-3-(2'-aryl)-6-methylisooxazolo[2,3-a]cyclopent[b]indoles (5b-h) and their structures 
were verified by FT-IR, 1H & 13C NMR spectroscopic methods and elemental analysis. 
The plausible mechanism is represented in Scheme 2. Hydroxylamine liberated in situ 
from hydroxylamine hydrochloride in the presence of pyridine undergoes 1,4 Michael-type 
addition to 4 in order to give the intermediate I which on protrophic shift yields the enolic 
intermediate II, stabilized through the keto form III. Then the intermediate III with the excess 
hydroxylamine yields the intermediate IV, which subsequently loses water molecule followed by 
cyclisation and deamination to yield the final product 5. 
The key intermediate 5-methyl-2-(thiophen-2'-ylidine)-1-oxo-1,2,3,8-tetrahydro 
cyclopent[b]indole (4a) in dry ethanol (20 mL) was added to an ice-cooled solution of 1.00 g of 
sodium hydride (degreased with petroleum ether) in dry benzene (10 mL). To this mixture 
malononitrile was added and the reaction mixture was refluxed on water bath for 5 hrs, to afford 
a single product (6a) (Scheme 1). Its FT-IR (KBr, cm-1) spectrum showed two characteristic 
peaks at 3191 cm-1 and 2219 cm-1 corresponding to NH and CN stretching vibrations 
respectively. Its 1H-NMR (400 MHz, DMSO-d6) spectrum in DMSO-d6 exhibited the following 
peaks. A three proton triplet at δ 1.222 was due to OCH2CH3 protons with J = 7.20 Hz. A three 
proton singlet at δ 2.404 was due to CH3 protons.A two proton singlet appeared at δ 3.863 was 
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due to C5-2H aliphatic protons. A quartet appeared at δ 4.583 was due to OCH2CH3 protons with 
J = 7.20 Hz. A multiplet appeared in the region between δ 7.187-7.361 was due to C3'-, C4'- and 
C5'- protons. A multiplet appeared in the region between δ 7.576-7.598 was due to C6- and C8- 
protons. One proton doublet appeared at δ 7.853 was due to C9- proton with J = 7.20 Hz. One 
proton singlet appeared at δ 11.747 was due to N-H proton. Its 13C NMR (100 MHz, DMSO-d6) 
spectrum indicates the presence of 22 carbons. All details attest the structure of the compound as 
5,10-dihydro-2-ethoxy-4-(thiophen-2'-yl)-7-methylpyrido[2,3-a]cyclopent[b]indole-3-
carbonitrile (6a). The generality (Scheme 1, Table 1) of the reaction was tested on 5-methyl-2-
(2'-arylidine)-1-oxo-1,2,3,8-tetrahydrocyclopent[b]indole derivatives (4b-h) with malononitrile, 
which gave the corresponding 5,10-dihydro-2-ethoxy-4-(2'-aryl)-7-methylpyrido[2,3-
a]cyclopent[b]indole-3-carbonitriles (6b-h) verified by FT-IR, 1H & 13C NMR spectroscopic 
methods and elemental analysis. 
The plausible mechanism (Scheme 3) for the formation of final product (6) was shown 
below. In the first step carbanion intermediate was generated from malononitrile under the basic 
condition, on Michael addition with α,β-unsaturated carbonyl intermediate (8) yields the dinitrile 
intermediate (VII). Then one of the symmetric carbonitrile (CN) carbon is attacked by the 
ethoxide ion generated in situ from NaOEt to give the imino-amino intermediates (VIII & IX). 
The amino intermediate (IX) on cyclodehydration (X) followed by aerial oxidation cum 
aromatization affords the final product (6). 
 
2.2. In vitro cytotoxicity 
For evaluating the cytotoxicity of the newly synthesized compounds, two different cancer 
cell lines were utilized: HeLa (cervix adeno carcinoma), MCF-7 (breast cancer). The viability of 
the cells were assessed by standard 3-(4,5-dimethylthiazol-2'-yl)-2,5-diphenyltetrazolium 
bromide (MTT)13 assay method in vitro. The in vitro cytotoxicity of 5-methyl-2-(2'-arylidine)-1-
oxo-1,2,3,8-tetrahydrocyclopent[b]indole (4), 4,9-dihydro-3-aryl-6-methylisooxazolo[2,3-a] 
cyclopent[b]indole (5) and 5,10-dihydro-2-ethoxy-4-aryl-7-methylpyrido[2,3-a]cyclopent[b] 
indole-3-carbonitrile (6) was performed by the MTT assay method against a pair of selected 
human breast cancer cell line (MCF-7) and HeLa (cervix adeno carcinoma) by means of a 
colorimetric assay (MTT assay) that measures mitochondrial dehydrogenase activity as an 
indication of cell viability after an exposure period of 24 hrs in the respective concentration 
 6 
range of 5-100 µM. Upon increasing the concentration of the compound, the results of MTT 
assay revealed that better growth inhibitory effect in a dose dependent manner against HeLa and 
MCF-7 cells with IC50 values generally in the micromolar concentrations. Ellipticine, a clinically 
used antitumor agent was also evaluated for positive control. The anticancer potency of these 
compounds was indicated by IC50 (the concentration that causes a 50% reduction of the cell 
growth). The obtained results were summarized in Table 2. 
As described in Table 2, some of the synthesized compounds illustrated moderate to 
potent anticancer activities against both cells. The achieved results indicated that the compounds 
showed selective cytotoxicity against HeLa. Among all, compound 6e and 6f showed nearly 
equipotent activity with ellipticine against HeLa. Among all, the most outstanding compound is 
6e which displayed stronger cytotoxic activity against HeLa with lowest IC50 value 22.16 μM 
and compound 6f showed almost equipotent to 6e, which was 25.70 μM. Moreover, the next 
most promising compound 5f, which depicted stronger cytotoxic activity against HeLa with IC50 
value 24.9 μM which was almost equipotent with that of the compounds 6e and 6f. Similar 
cytotoxic analysis carried out using standard drugs, shown that the IC50 value of Cisplatin, a 
major chemotherapeutic agent was 30µM in case of HeLa cell line. This result reveals that, the 
newly synthesized compounds like 5f, 6e and 6f have significantly lower IC50 values when 
compared to the conventional chemotherapeutic drug Cisplatin. 
Compounds 5f, 6e and 6f were displayed significant IC50 values of 28.46, 19.23 and 
32.45 μM nearly equipotent activity with ellipticine against MCF-7, respectively. Furthermore 
compounds 5e and 6g showed good cytotoxic activity against HeLa with IC50 values 45.9 and 
38.98 μM, respectively and the same compounds displayed IC50 values 39.66 and 47.19 μM 
against MCF 7. The intermediates 4 displayed significant cytotoxic activity against both HeLa 
and MCF 7 cell lines. In general it was found that all synthesized compounds showed selective 
cytotoxic activity against HeLa cells. Further comparing with the IC50 values of other drugs like 
5-Fluorouracil and methotrexate under similar conditions show that, the IC50 values for the 
synthesized compounds are significantly lower than their conventional counter parts, suggesting 
better cytotoxic efficacy of these compounds. 
The present study investigated the effect of several substituents and from the results of 
cytotoxicity of the synthesized hetero annulated cyclopent[b]indoles; the following primarily 
structure-activity relationships can be derived: 
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 Among the newly synthesized compounds, compounds 6e and 6f displayed stronger 
cytotoxic activity against HeLa. This might be due to the presence of pyrido moiety 14 and 
the cyano group which enhanced the cytotoxic activity. The stronger electron withdrawing 
ability of the cyano group, which played an important role in anticancer effect.15 
 Subsequently, compounds 5f and 5e also showed better cytotoxic activity with IC50 values < 
46 μM against HeLa which was due to the presence of isoxazolo moiety16 which enhanced 
the cytotoxic activity. It was observed that the intermediates showed least cytotoxic activity 
than the cyclised products. 
 
2.3. Molecular docking studies 
Molecular docking is vital role to find an unfailing and more specific depiction of the 
biologically active molecules at the atomic level and also, to afford a new insight that is able to 
use to endeavour novel therapeutic agents. In an effort to get deeper insight into the inhibitory 
potency of the newly synthesized hetero annulated cyclopent[b]indoles to better understand the 
mechanism of cytotoxicity and structure–activity relationships (SAR), we performed docking 
studies using Autodock4.0 tool.17 All the synthesized compounds (4a-h, 5a-h, 6a-h), the 
standard ellipticine and 5-Fluorouracil were docked by human protein kinase CK2 receptor (PDB 
ID: 3OWJ)18 and ligand was prepared for docking analysis with MGLTools 1.5.6. In the 
molecular docking studies of synthesized molecules displayed good binding energy towards the 
target protein ranging from -6.11 kcal/mol to -9.70 kcal/mol.  
We envisaged the binding orientation, the standards, Ellipticine forms a hydrogen bond 
by interaction of the NH group of the carbazole moiety with the nitrogen atom of ASP175 
(2.198A°) with a binding energy is -7.58 kcal/mol (Fig. 3), 5-Fluorouracil forms three hydrogen 
bonding interaction of oxygen atoms of TYR50:HN (2.049A°), LYS68:HZ1 (1.952A°), 
respectively and hydrogen atom of NH group in 5-fluorouracil with SER51:OG (2.071A°) with 
binding energy is -4.00 kcal/mol (Fig. 4).  
5-Methyl-2-(aryl-2'-ylidine)-1-oxo-1,2,3,8-tetrahydrocyclopent[b]indole (4) compounds 
showed the docking scores ranging from -9.30 kcal/mol to -8.20 kcal/mol. Among them, the 
compound (4e) displayed the best lowest binding energy (-8.71 kcal/mol), ligand efficiency (-
0.35 kcal/mol) and it forms four hydrogen bonds by the interactions of LYS68:HZ3 (1.964Ao), 
ASP175:HN (1.620Ao) with phenyl ring two OCH3 group oxygen atoms and the other 
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interactions of 1-oxo-1,2,3,8-tetrahydrocyclopent[b]indole ring NH group and C=O group with 
VAL116:O and VAL116:HN with respective bond residues are 1.986Ao & 1.715Ao. It was 
shown in Fig.5. Among all the compounds (4 a-h), in comparison with standard drugs ellipticine 
and 5-Fluorouracil, nearly all the synthesised compounds demonstrated better binding energy. 
4,9-Dihydro-3-(aryl-2'-yl)-6-methyl-isooxazolo[2,3-a]cyclopent[b]indole (5) compounds 
showed the docking scores ranging from -9.56 kcal/mol to -7.17 kcal/mol. Among them, the 
compound (5e) revealed the best lowest binding energy (-9.56 kcal/mol), ligand efficiency (-0.37 
kcal/mol) and it forms two hydrogen bonds by the interactions of VAL116:O with 1-oxo-1,2,3,8-
tetrahydrocyclopent[b]indole ring NH group hydrogen atom and the other interactions of phenyl 
ring 4-OCH3 group oxygen atom with LYS68:HZ3 with respective bond residues are 2.006A
o & 
1.943Ao. It was shown in Fig.6. Among all the compounds (5 a-h), in comparison with standard 
drugs ellipticine and 5-Fluorouracil, almost all the synthesised compounds displayed enhanced 
binding energy. 
5,10-Dihydro-2-ethoxy-4-(aryl-2'-yl)-7-methyl-pyrido[2,3-a]cyclopent[b]indole-3-
carbonitrile (6) compounds showed the docking scores ranging from -8.67 kcal/mol to -6.11 
kcal/mol. Among them, the compound (6h) displayed the best lowest binding energy (-6.11 
kcal/mol), ligand efficiency (-0.24 kcal/mol) and it forms two hydrogen bonds by the interactions 
of LYS158:HZ3 with OC2H5 group oxygen atom and the other interactions of pyridine ring 
nitrogen atom with TYR196:HH with respective bond residues are 1.900Ao & 2.220Ao. It was 
shown in Fig.7. Among all the compounds (6 a-h), in comparison with standard drugs ellipticine 
and 5-Fluorouracil, with expect from 6d, more or less all other synthesised compounds showed 
moderate binding energy. 
The proposed binding mode can assist us to superior understand the nature of interactions 
of this (4a-h, 5a-h, 6a-h) synthesised compounds. In comparison with the standard ellipticine 
and 5-Fluorouracil, with the exception of compound 6d almost all the other synthesised 
compounds appeared potent binding energy. The compounds 4d, 4e, 5e and 5f exhibited good 
binding interaction compared to all other compounds and standard drugs. In general it was found 
that all the synthesised compounds (4a-h, 5a-h, 6a-h) have potent binding interactions compared 
to standard drugs (ellipticine and 5-Fluorouracil). The results attained from in vitro cytotoxic 
studies and molecular docking studies indicated that the presence of hetero annulated 
substituents of cyclopent[b]indole may enhances the efficacy towards the biological activities. 
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The docking studies of human protein kinase CK2 receptor with synthetic compounds 
(4a-h, 5a-h, 6a-h, Ellipticine and 5-Flurouracil) were analyzed for the lowest binding energy, 
lowest ligand efficiency and more than numbers of hydrogen bonds were formed for the best 
interaction. The length of bond distance between the receptor and ligand below 3Ao is the best. In 
our results, all the synthetic compounds were docked with human protein kinase CK2 receptor 
and it showed proper interactions but except 6d compound. In this data was obtained by docking 
analysis is available in the following Table 3. 
 
3. Conclusion 
The condensation reaction of 5-methyl-1-oxo-1,2,3,8-tetrahydro cyclopent[b]indole (2) 
with aryl / heteroaryl aldehydes were optimised to obtain cleaner 5-methyl-2-arylidine-1-oxo-
1,2,3,8-tetrahydrocyclopent[b]indoles (4) in good yields. The resulting cyclopent[b]indoles were 
found to have α,β-unsaturated carbonyl system. This was taken advantage and these α,β-
unsaturated carbonyl cyclopent[b]indoles derivatives were condensed with 1,2-nucleophiles like 
hydroxylamine hydrochloride and as well as malononitrile to yield 4,9-dihydro-3-aryl/heteroaryl-
6-methylisooxazolo[2,3-a]cyclopent[b]indoles (5) and 5,10-dihydro-2-ethoxy-4-aryl/heteroaryl-
7-methylpyrido[2,3-a]cyclopent[b]indole-3-carbonitriles (6), respectively. Among the newly 
synthesized compounds, compounds 6e and 6f displayed stronger cytotoxic activity against 
HeLa. This might be due to the presence of pyrido moeity and the cyano group which enhanced 
the cytotoxic activity. Subsequently, compounds 5e and 5f also showed better cytotoxic activity 
with IC50 values < 46 μM against HeLa which was due to the presence of isoxazolo moiety 
which enhanced the cytotoxic activity. The results achieved from in vitro cytotoxic studies and 
molecular docking studies indicated that the presence of hetero annulated substituents of 
cyclopent[b]indole may enhance the efficacy towards the biological activities. 
 
Experimental Section  
General: 
Melting points (M.p.) were determined on a Mettler FP 51 apparatus (Mettler 
Instruments, Switzerland) and are uncorrected. They are expressed in degree centigrade (°C). 
A Nicolet Avatar Model FT-IR spectrophotometer was used to record the IR spectra (4000–400 
cm-1). 1H, 13C and 2D NMR spectra were recorded on Bruker AV 400 (400 MHz (1H) and 100 
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MHz (13C)) spectrometers using tetramethylsilane (TMS) as an internal reference. The chemical 
shifts are expressed in parts per million (ppm). Coupling constants (J) are reported in hertz (Hz). 
The terms s, d, t, dd refer to singlet, doublet, triplet and doublet of doublet, respectively, b s 
refers to a broad singlet. Microanalyses were performed on a Vario EL III model CHNS analyzer 
(Vario, Germany) at the Department of Chemistry, Bharathiar University. When known 
compounds had to be prepared according to literature procedures, pertinent references are given. 
The purity of the products was tested by TLC with plates coated with silica gel-G using 
petroleum ether and ethyl acetate in the ratio of 1:1 as developing solvents. Columns packed with 
activated silica gel (60-120 mesh) were used to purify the product. 
 
Synthesis 
General procedure for the synthesis of 5-methyl-2-(aryl-2'-ylidine)-1-oxo-1,2,3,8-
tetrahydrocyclopent[b]indole (4) 
An equimolar mixture of 5-methyl-1-oxo-1,2,3,8-tetra hydrocyclopent[b]indole (2, 0.005 
mol) and arylaldehyde (3, 0.005 mol) was reacted with 25 mL of a 5% alcoholic potassium 
hydroxide solution and stirred at room temperature for 24 hrs. The product precipitated as a 
yellow crysatalline solid, was filtered off and washed with 50% ethanol. A further crop of 
condensation product was obtained on neutralization with 1:1HCl and further diluted with water. 
Thus the combined product was recrystallised from ethylacetate to yield the respective 5-methyl-
2-(aryl-2'-ylidine)-1-oxo-1,2,3,8-tetrahydrocyclopent[b]indole (4). 
 
5-Methyl-2-(thiophen-2'-ylidine)-1-oxo-1,2,3,8-tetrahydrocyclopent[b]indole (4a) 
Yellow solid; M.p. 204-206 ºC Yield = 93%; FT-IR (KBr, cm-1) νmax: 3187, 1662; 1H NMR (400 
MHz, DMSO-d6) (ppm) δ: 2.404 (s, 3H, C5-CH3), 3.862 (s, 2H, C3-H2), 7.186-7.241 (m, 2H, C4-, 
C6-H), 7.340 (d, 1H, C7-H, J = 8.40 Hz), 7.576-7.602 (m, 3H, C3'-, C4'-, C5'-H), 7.866 (t, 1H, C2-
CH, J = 4.00 Hz), 11.747 (s, 1H, NH); 13C NMR (100 MHz, DMSO-d6) (ppm) δ: 21.041, 26.120, 
113.358, 120.852, 122.767, 123.584, 128.305, 128.741, 129.118, 130.925, 132.980, 137.856, 
137.945, 138.913, 140.889, 141.933, 181.267; Anal. Calcd. for: C17H13NOS: C, 73.09; H, 4.69; N, 
5.01; S, 11.48. Found: C, 73.19; H, 4.60; N, 5.09; S, 11.39%. 
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General procedure for the synthesis of 4,9-dihydro-3-(aryl-2'-yl)-6-methyl-isooxazolo[2,3-a] 
cyclopent[b]indole (5):  
The respective 5-methyl-2-(aryl-2'-ylidine)-1-oxo-1,2,3,8-tetrahydrocyclopent[b] indole 
(4, 0.001 mol) was refluxed with hydroxylamine hydrochloride (0.014 mol) in dry pyridine (5 
mL) at 130 °C for 8 hrs. The reaction was monitored by TLC. After completion of the reaction, 
the crude mixture was poured into ice-cold water and neutralized with 5N HCl, the resulting 
semi-solid that separated was extracted with ethyl acetate. The combined organic layers were 
dried over anhydrous sodium sulphate. It was then purified by column chromatography over 
silica gel using petroleum ether:ethyl acetate (98:2) to yield the corresponding, 4,9-dihydro-3-
(aryl-2'-yl)-6-methylisooxazolo[2,3-a]cyclopent[b]indole (5). The product obtained was 
recrystallised from ethanol. 
 
4,9-Dihydro-3-(thiophen-2'-yl)-6-methylisooxazolo[2,3-a]cyclopent[b]indole (5a) 
Yellow solid; M.p. 180-182 ºC Yield = 63%; FT-IR (KBr, cm-1) νmax: 3342, 1662; 1H NMR (400 
MHz, DMSO-d6) (ppm) δ: 2.390 (s, 3H, C6-CH3), 3.790 (s, 2H, C4-H2), 7.041 (d, 1H, C8-H, J = 
8.40 Hz), 7.160-7.180 (m, 1H, C7-H), 7.358-7.411 (m, 3H, C3'-, C4'-, C5'-H), 7.472 (s, 1H, C5-H), 
11.265 (s, 1H, NH); 13C NMR (100 MHz, DMSO-d6) (ppm) δ: 21.06, 28.89, 112.34, 112.88, 
115.87, 119.36, 122.41, 123.33, 125.87, 127.65, 128.13, 129.09, 130.21, 136.13, 140.02, 140.27, 
147.07, 148.55; Anal. Calcd. for: C17H12N2OS: C, 69.84; H, 4.14; N, 9.58; S, 10.97. Found: C, 
69.78; H, 4.20; N, 9.51; S, 10.90%. 
 
General procedure for the synthesis of 5,10-dihydro-2-ethoxy-4-(aryl-2'-yl)-7-methyl-
pyrido[2,3-a]cyclopent[b]indole-3-carbonitrile (6):  
A solution of respective 5-methyl-2-(aryl-2'-ylidine)-1-oxo-1,2,3,8-tetrahydro 
cyclopent[b]indole (4, 0.001 mol) in dry ethanol (20 mL) was added to an ice-cooled solution of 
1.00 g of sodium hydride (degreased with petroleum ether) in dry benzene (10 mL). To this 
mixture malononitrile (0.005 mol) was added and the reaction mixture was refluxed on a water 
bath for 5 hrs. The reaction was monitored by TLC indicated the formation of product. After the 
completion of the reaction the mixture was poured into ice-water and neutralized with 1:1 HCl. 
The brown solid separated was then filtered and dried. It was then purified by column 
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chromatography over silica gel using petroleum ether:ethyl acetate (95:5) as eluent to yield 5,10-
dihydro-2-ethoxy-4-(aryl-2'-yl)-7-methylpyrido[2,3-a]cyclopent[b]indole-3-carbonitrile (6). 
 
5,10-Dihydro-2-ethoxy-4-(thiophen-2'-yl)-7-methylpyrido[2,3-a]cyclopent[b]indole-3-
carbonitrile (6a) 
Yellow solid; M.p. 208-210 ºC Yield = 69%; FT-IR (KBr, cm-1) νmax: 3191, 2219, 1662; 1H 
NMR (400 MHz, DMSO-d6) (ppm) δ: 1.222 (s, 3H, C2-OCH2CH3), 2.404 (s, 3H, C7-CH3), 3.863 
(s, 2H, C5-H2), 4.583 (q, 2H, C2-OCH2CH3, J = 7.20 Hz), 7.187-7.361 (m, 3H, C3'-, C4'-, C5'-H), 
7.576-7.598 (m, 2H, C6-, C8-H), 7.853 (d, 1H, C9-H, J = 7.20 Hz), 11.747 (s, 1H, NH); 
13C NMR 
(100 MHz, DMSO-d6) (ppm) δ: 20.979, 21.027, 26.049, 26.106, 28.923, 113.277, 113.410, 
120.749, 120.850, 122.699, 123.474, 123.578, 128.219, 128.299, 128.733, 129.105, 130.835, 
130.922, 132.869, 132.973, 137.863; Anal. Calcd. for: C22H17N3OS: C, 71.14; H, 4.61; N, 11.31; 
S, 8.63 Found: C, 71.04; H, 4.69; N, 11.23; S, 8.72%. 
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